TREATMENTS &
RESEARCH

Search the
latest
treatment
information
here.

Dr. Huntley's
Diagnosis
Checklist

Have a symptom?
See what questions
a doctor would ask.
 
Articles » Hydroxyurea in Pediatric Patients with Sickle Cell Disease: NHLBI
 

Hydroxyurea in Pediatric Patients with Sickle Cell Disease: NHLBI

Article title: Hydroxyurea in Pediatric Patients with Sickle Cell Disease: NHLBI

Conditions: Sickle cell anemia

Source: NHLBI


HYDROXYUREA IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE


FACT SHEET




  • Sickle cell anemia is a major public health problem affecting a significant portion of the African-American population.

  • In 1995, an NHLBI clinical trial of hydroxyurea in adults over the age of 18 demonstrated, for the first time, an effective therapy for reducing painful episodes in severely affected adults with sickle cell anemia.

  • Although hydroxyurea has been approved by the FDA for adults with sickle cell disease, there is concern about the potential toxicity of hydroxyurea in children, and its effects on growth and development.

  • Therefore, hydroxyurea is not recommended for children at this time. However, clinicians are interested in determining its benefits, if any, in children particularly in preventing organ damage and improving long-term survival.

  • A Phase I/II study ( PED-HUG) was supported by the NHLBI to determine the therapeutic dose of hydroxyurea in children with 3 or more painful episodes per year and to identify any short-term toxicities.

  • The study was conducted in 4 of the 10 Comprehensive Sickle Cell Centers and 3 other clinical sites in children ages 5 to 15 years.

  • The PED-HUG recently reported data on 50 children followed at the maximum tolerated dose of hydroxyurea for one year. There were no significant side effects with regard to growth and development or major organ dysfunction.

  • Hydroxyurea was observed to increase fetal hemoglobin in a manner similar to that seen in the adults with sickle cell anemia, and is considered to be safe in children between the ages of 5 and 15 years.

  • Further clinical research is needed in children to investigate the effectiveness of hydroxyurea in preventing long-term damage to major organs. This will be of great benefit if spleen function can be preserved, and the deleterious effects to the central nervous system, lungs and kidneys can be prevented.




June 1998


Home Page   Sickle Cell Information for the General Public



Please send us your feedback, comments, and questions
by using the appropriate link on the page, Contact the NHLBI.

Note to users of screen readers and other assistive technologies: please report your problems here.

 » Next page: Hyperparathyroidism: NIDDK

Rate This Website

What do you think about the features of this website? Take our user survey and have your say:

Website User Survey

Medical Tools & Articles:

Tools & Services:

Medical Articles:

Forums & Message Boards

 
HONcode We subscribe to the HONcode principles

By using this site you agree to our Terms of Use. Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs. Please see our Terms of Use.

Home | Symptoms | Diseases | Diagnosis | Videos | Tools | Forum | About Us | Terms of Use | Privacy Policy | Site Map | Advertise